Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.

MLA

Dirven, Linda, et al. “Establishing Anchor-Based Minimally Important Differences for the EORTC QLQ-C30 in Glioma Patients.” Neuro-Oncology, vol. 23, no. 8, Aug. 2021, pp. 1327–36. EBSCOhost, https://doi.org/10.1093/neuonc/noab037.

APA

Dirven, L., Musoro, J. Z., Coens, C., Reijneveld, J. C., Taphoorn, M. J. B., Boele, F. W., Groenvold, M., van den Bent, M. J., Stupp, R., Velikova, G., Cocks, K., Sprangers, M. A. G., King, M. T., Flechtner, H.-H., & Bottomley, A. (2021). Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. Neuro-Oncology, 23(8), 1327–1336. https://doi.org/10.1093/neuonc/noab037

Chicago

Dirven, Linda, Jammbe Z Musoro, Corneel Coens, Jaap C Reijneveld, Martin J B Taphoorn, Florien W Boele, Mogens Groenvold, et al. 2021. “Establishing Anchor-Based Minimally Important Differences for the EORTC QLQ-C30 in Glioma Patients.” Neuro-Oncology 23 (8): 1327–36. doi:10.1093/neuonc/noab037.